Biotech News News 11 December 2025

Biogen Stock (NASDAQ: BIIB) News and Forecasts for Dec. 20, 2025: RBC’s $210 Target, Leqembi Catalysts, and What Investors Are Watching

Biogen Inc. stock (NASDAQ: BIIB) is ending the week on a stronger note after a sharp, high-volume move on Friday’s session—an attention-grabbing setup heading into late December when liquidity often thins and headlines can move shares quickly. As of Saturday,

20 December 2025

Biotech News·Earnings Reports·Investment Tips·Stock Analysis·Stock Market

Insmed (INSM) Stock News and Forecasts on Dec. 20, 2025: Brinsupri Trial Miss, Truist Upgrade, and Updated Price Targets

December 20, 2025 — Insmed Incorporated (NASDAQ: INSM) is ending the week in “re-pricing mode” after a mid-stage clinical setback jolted investor expectations, sparked sharp volatility, and triggered a round of analyst price-target revisions. By Friday’s close (the last U.S.

20 December 2025

Biotech News·Financial Forecasts·Investment Analysis·Stock Market

BioMarin (BMRN) Stock Surges on $4.8B Amicus Deal: Latest News, Analyst Forecasts, and What to Watch Next (Dec. 20, 2025)

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) ended Friday’s session sharply higher after announcing a blockbuster rare-disease acquisition that immediately reframed the company’s growth story. Shares closed at $61.15, up about 17.7% on the day, with trading volume far above typical levels—classic

20 December 2025

Biotech News·Financial Forecasts·Investment Analysis·Mergers & Acquisitions·Stock Market

Disc Medicine (NASDAQ: IRON) Stock Tumbles on Insider-Selling Headlines as Bitopertin FDA Decision Nears — News, Analyst Forecasts, and What to Watch (Dec. 19, 2025)

Disc Medicine, Inc. stock (NASDAQ: IRON) sank sharply on Friday, Dec. 19, 2025, with IRON down about 10% in late-morning trading and swinging through a wide intraday range that, at one point, dipped into the low $70s before rebounding toward

19 December 2025

Biotech News·FDA Approvals·Insider Trading·Investment Analysis·Stock Market

Insmed Stock (INSM) Rebounds on Dec. 19, 2025 After BiRCh Trial Miss: Latest News, Analyst Forecasts, and What Comes Next

December 19, 2025 — Insmed Incorporated (NASDAQ: INSM) is back in focus today after a sharp, news-driven selloff on Thursday and a noticeable bounce on Friday. As of 15:46 UTC on Dec. 19, INSM shares were trading around $174.90, up

19 December 2025

Analyst Forecasts·Biotech News·Financial Updates·Investment Strategies·Stock Market

Processa Pharmaceuticals (PCSA) Stock: Phase 2 Breast Cancer Update, 1-for-25 Reverse Split, and What Wall Street Is Watching on Dec. 18, 2025

December 18, 2025 — Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) is back on traders’ radar after the company reported fresh clinical observations from its Phase 2 breast cancer program and implemented another reverse stock split to consolidate shares. The result: a

18 December 2025

Biotech News·Clinical Trials·Investment Analysis·Stock Market

Altimmune (ALT) Stock News Today (Dec. 17, 2025): Pemvidutide Catalysts, CEO Transition, and Wall Street Price Targets

Altimmune, Inc. (NASDAQ: ALT) is back in the biotech spotlight on December 17, 2025—less because the company suddenly became “safe,” and more because it’s heading into the kind of binary stretch that turns small-cap biotech charts into roller coasters: a

17 December 2025

Biotech News·Company Updates·Financial Analysis·Investing·Stock Market

ImmunityBio (IBRX) Stock in Focus on Dec. 15, 2025: EMA’s ANKTIVA Nod, Analyst Targets, and What Comes Next

December 15, 2025 — ImmunityBio, Inc. (NASDAQ: IBRX) is back on investors’ radar today as fresh coverage and new analysis dig into a major European regulatory milestone for its lead therapy ANKTIVA (nogapendekin alfa inbakicept). The market’s obsession is simple:

15 December 2025

Biotech News·Financial Forecasts·Investment Analysis·Stock Market

CSL Limited Stock (ASX:CSL) After the Bell on Dec. 12, 2025: Buyback Update, HEMGENIX Five‑Year Data, Analyst Forecasts, and What to Watch Before the Next Open

CSL Limited shares finished Friday’s session firmly higher, with the biotech giant benefiting from a broader rebound in Australian healthcare stocks and fresh attention on two CSL-specific threads: its ongoing on-market share buyback and the latest long-term durability data for

13 December 2025

Analyst Forecasts·Biotech News·Share Buybacks·Stock Market

Eli Lilly (LLY) Stock After Hours on December 11, 2025: Retatrutide Breakthrough, $6B Plant — and What to Watch Before Friday’s Open

Eli Lilly and Company (NYSE: LLY) ended Thursday’s session back near record territory as Wall Street digested stunning new weight‑loss data from its experimental obesity drug retatrutide, a massive new U.S. manufacturing investment, and fresh signs of global expansion for

11 December 2025

Biotech News·Earnings Reports·Investing·Pharmaceuticals·Stock Market

Vera Therapeutics (VERA) Stock Outlook: December 11, 2025 Update on Public Offering, Atacicept BLA and Wall Street Targets

Vera Therapeutics, Inc. (NASDAQ: VERA) is back center stage on December 11, 2025, as traders digest a fresh equity offering, strong late‑stage clinical data, and a newly filed Biologics License Application (BLA) for its lead drug, atacicept, in IgA nephropathy

11 December 2025

Biotech News·Investment Strategies·Market Updates·Pharmaceutical Industry·Stock Analysis

Belite Bio (NASDAQ: BLTE) Stock: DRAGON Trial Breakthrough, $350 Million Offering and Outlook After a 130% Rally

Belite Bio, Inc. (NASDAQ: BLTE) has turned into one of 2025’s most closely watched biotech stories. On the back of a pivotal Phase 3 win in Stargardt disease and a large equity raise, the small-cap ophthalmology specialist has seen its

11 December 2025

Biotech News·Clinical Trials·Financial Outlook·Investment Analysis·Stock Market

Biotech News News 11 December 2025 - 20 December 2025